Nicholas W. Van Hise

Statistics

Publications

Citations

264

H-Index

Active since

2016

Affiliations

Infectious Disease Consultants(Current)

Harvard University

Western University

Yale University

Brigham and Women's Hospital

Nicholas W. Van Hise is an author at Infectious Disease Consultants specializing in pharmacotherapy, critically ill patient dosing, and critical illness dosing.

Publications per year

2016–2025

Publications

Efficacy of Oral Vancomycin in Preventing Recurrent<i>Clostridium difficile</i>Infection in Patients Treated With Systemic Antimicrobial Agents: Table 1.

Nicholas W. Van Hise, Alex Bryant, Erin Hennessey et al. · Clinical Infectious Diseases · 2016 · 91 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +13

Treatment of Acute Osteomyelitis with Once-Weekly Oritavancin: A Two-Year, Multicenter, Retrospective Study

Nicholas W. Van Hise, Vishnu Chundi, Vishal Didwania et al. · Drugs - Real World Outcomes · 2020 · 43 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

PUNCH CD3-OLS: A Phase 3 Prospective Observational Cohort Study to Evaluate the Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA) in Adults With Recurrent <i>Clostridioides difficile</i> Infection

Paul Feuerstadt, Teena Chopra, W Knapple et al. · Clinical Infectious Diseases · 2024 · 32 citations · Full text

Life Sciences, Infectious Diseases, Pharmacotherapy +16

Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS‐CoV‐2

Russell M. Petrak, Nathan C. Skorodin, Nicholas W. Van Hise et al. · Clinical and Translational Science · 2020 · 22 citations · Full text

Medicine, Immunology, Pharmacotherapy +17

Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS-CoV-2

Russell M. Petrak, Nathan C. Skorodin, Nicholas W. Van Hise et al. · medRxiv · 2020 · 20 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +15

1–5 of 9